Evidence map›Paper›PMID 38155996›Full record

ArticleArchive of clinical cases2023

Superscan on

Daniel Felipe Galindo Cortes, Helen Mejia Efeer, Sandra Caro Perdomo, Nathalie Hernandez Hidalgo

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Archive of clinical cases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Efficacy and safety of Lutetium-177 (Annals of nuclear medicine · 2026
    Article
  2. Frailty and [Theranostics · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Daniel Felipe Galindo CortesFundacion Universitaria Sanitas, Bogota, Colombia.
Helen Mejia EfeerFundacion Universitaria Sanitas, Bogota, Colombia.
Sandra Caro PerdomoInstituto Nacional de Cancerologia, Bogota, Colombia.
Nathalie Hernandez HidalgoInstituto Nacional de Cancerologia, Bogota, Colombia.
Fundación Universitaria Sanitas · COInstituto Nacional de Cancerología · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is the second most common malignancy in men worldwide, with a good prognosis when is detected and treated in early stages, but, when it presents progression to castration-resistant metastatic prostate cancer, most of the cases will have bone metastasis, decreasing the quality of life and life expectancy. For the evaluation of the disease in the routinary clinical practice,

Indexed as

68Ga-PSMA PET/CTmetastatic prostate carcinomasuperscan

Identifiers

PMID38155996
PMCPMC10753930
OpenAlexW4390419037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.